ArabFinance: October Pharma (OCPH) announced that its board of directors has endorsed the estimated budget for 2022, according to a statement filed to the Egyptian Exchange (EGX).

Under the estimated budget, the company targets a net profit after tax of EGP 135 million in 2022.

Moreover, the budget estimates the company’s 2022 revenue at EGP 775 million.

As per the investment budget, the company aims at acquiring fixed assets valued at EGP 65.82 million in 2022.

October Pharma is an Egypt-based company engaged in the production of human pharmaceutical preparations.

The company’s major shareholders include the Arab Company for Drug Industries and Medical Appliances as well as the Saudi-Egyptian Industrial Investment Company.